Xenetic Biosciences, Inc. (XBIO)

Expanding the Potential of CAR T Cell Therapy

Xenetic Biosciences is a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens.

More About Us

Combating Disease Through Innovative Therapies

Product Pipeline

Platform

Personalized CAR T platform targeting cancers with a patient- and tumor-specific approach.

XCART Platform

Transformative Technologies

Our proprietary and patented technologies are being utilized to create life-changing therapies.

Our Novel Technologies

Latest News

Nov 12, 2021

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Sep 09, 2021

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

Stock Information • View Detailed Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.

Price

Change

Volume

Day Range

52 Week Range

Investor Presentation

View Investor Presentation

Get Email Alerts

Stay informed about our latest news and updates